Rechercher des projets européens

Plus de 40 projets européens trouvés

Recherche sur 125080 projets européens

 TERMINÉ 

Clinical proof of concept through a randomised phase II study: a combination of immunotherapy and stereotactic ablative radiotherapy as a curative treatment for limited metastatic lung cancer (IMMUNOSABR)

Date du début: 1 janv. 2017, Date de fin: 31 déc. 2022,

IMMUNOSABR is geared towards opening up a new paradigm in treating metastatic cancer by obtaining clinical proof of concept for a novel bi-modal curative treatment strategy. High precision stereotactic ablative radiotherapy (SABR) is combined with immunotherapy to form a powerful synergistic anti-tumour strategy. The approach relies on the direct cytotoxic effect of SABR, the abscopal effect of ra ...
Voir le projet

 17

 TERMINÉ 

Genomics of Chromosome Architecture and Dynamics in Single Cells (GoCADiSC)

Date du début: 1 mars 2017, Date de fin: 28 févr. 2022,

"The spatial architecture of mammalian interphase chromosomes, each consisting of tens of megabases of DNA, poses an intriguing topological problem and is relevant for various nuclear functions. A major challenge is that chromosome architecture exhibits substantial stochastic cell-to-cell variation. To unravel the principles of chromosome organization, new single-cell genome-wide approaches that c ...
Voir le projet

 1

 TERMINÉ 

Generation of the CanPath prototype - a platform for predictive cancer pathway modeling (CanPathPro)

Date du début: 1 mars 2016, Date de fin: 28 févr. 2021,

Recent developments in omics technologies demand implementation of systems biology approaches to facilitate analysis and interpretation of the generated complex datasets.This is essential for biotechnological as well as preclinical and clinical applications. In comparison to previous approaches, most cancer relevant studies are confined to pattern recognition or at best modelling of single pathway ...
Voir le projet

 9

 TERMINÉ 

Towards enduring mouse resources and services advancing research into human health and disease (INFRAFRONTIER2020)

Date du début: 1 janv. 2017, Date de fin: 31 déc. 2020,

The INFRAFRONTIER RI integrates European Mouse Clinics and the European Mouse Mutant Archive with the common goal to ensure access to mouse models for basic research of human health and disease, and to translate this knowledge into therapeutic approaches for the benefit of the European society. The expanded INFRAFRONTIER2020 network, coordinated by the INFRAFRONTIER GmbH, includes 3 SMEs and is st ...
Voir le projet

 33

 TERMINÉ 

Regulated Assembly of Molecular Machines for DNA REPAIR: a Molecular Analysis training Network (DNAREPAIRMAN)

Date du début: 1 janv. 2017, Date de fin: 31 déc. 2020,

The European Training Network DNAREPAIRMAN aims to train a new generation of innovative young scientists in cutting edge biophysical research methodology to address central questions in biology concerning the mode of action of critical molecular machines with relevance for human health. The Network consists of a highly collaborative consortium consisting of 12 participants coming from academia, in ...
Voir le projet

 8

 TERMINÉ 

Cancer treatment during pregnancy: from fetal safety to maternal efficacy (CRADLE)

Date du début: 1 oct. 2015, Date de fin: 30 sept. 2020,

The evolution in drug regulation of the last 50 years has left pregnant women and their fetuses orphaned. This is particularly problematic for cancer during pregnancy, which raises a difficult and conflicting medical ethical decision process and which has recently become increasingly frequent. In 2012 we published the first prospective study indicating that antenatal exposure to cancer treatment c ...
Voir le projet

 2

 TERMINÉ 

Targeting SYNthetic lethal interactions for new cancer treatments TRAINing network (SYNTRAIN)

Date du début: 1 sept. 2016, Date de fin: 31 août 2020,

Breast and ovarian cancer constitute serious health challenges in the EU. To identify new improved cancer therapeutic approaches, we will pursue a multi-facetted synthetic lethal approach, which takes advantage of the inherent genetic instability of cancer cells. Most mutations acquired by cancer cells do not cause lethality, but the very same mutations may cause cell death when a second gene in a ...
Voir le projet

 10

 TERMINÉ 

Breast CAncer STratification: understanding the determinants of risk and prognosis of molecular subtypes (B-CAST)

Date du début: 1 sept. 2015, Date de fin: 31 août 2020,

Breast tumours are heterogeneous, and result from the complex interplay of multiple lifestyle/environmental and genetic risk factors. Through the EU-funded COGS project, we have identified a large number of germline variants that influence the risk of breast cancer. In combination, these variants can identify women at wide ranges of genetic risk, even in the absence of family history of breast can ...
Voir le projet

 13

 TERMINÉ 

From haplotype to phenotype: a systems integration of allelic variation, chromatin state and 3D genome data (HAP-PHEN)

Date du début: 1 sept. 2015, Date de fin: 31 août 2020,

High-throughput sequencing methods are breaching the barrier of $1000 per genome. This means that it will become feasible to sequence the genomes of many individual and create a deep catalog of the bulk of human genetic variation. A great task will lie in assigning function to all this genetic variation. Genome wide association studies have already shown that 40% of all loci significantly associat ...
Voir le projet

 1

 TERMINÉ 

DC-based immunotherapy to treat Malignant Mesothelioma (H2020MM04)

Date du début: 1 janv. 2016, Date de fin: 31 déc. 2019,

Asbestos is one of the major occupational carcinogens. The European Union has an extensive history of protecting workers and consumers against asbestos and even adopted a resolution 2012/2065(INI) ‘on asbestos related occupational health threats and prospects for abolishing all existing asbestos’ last year. Although asbestos is banned, it is still massively present in the built environment. Millio ...
Voir le projet

 8

 TERMINÉ 

Molecularly guided trials with specific treatment strategies in patients with advanced newly molecular defined subtypes of colorectal cancer (MoTriColor) (MoTriColor)

Date du début: 1 oct. 2015, Date de fin: 30 sept. 2019,

Colorectal cancer (CRC) is increasingly being recognized as a heterogeneous disease with distinct molecular subtypes. These subtypes have different biological processes at the basis of their disease and consequently their prognosis and responses to therapy are also different.We have previously developed molecular diagnostic assays using a single platform on routine FFPE tumour biopsies. These assa ...
Voir le projet

 12

 TERMINÉ 

Infrastructure for NMR, EM and X-rays for translational research (iNEXT)

Date du début: 1 sept. 2015, Date de fin: 31 août 2019,

Structural biology provides insight into the molecular architecture of cells up to atomic resolution, revealing the biological mechanisms that are fundamental to life. It is thus key to many innovations in chemistry, biotechnology and medicine such as engineered enzymes, new potent drugs, innovative vaccines and novel biomaterials.iNEXT (infrastructure for NMR, EM and X-rays for Translational rese ...
Voir le projet

 23

 TERMINÉ 

Advancing Smart Optical Imaging and Sensing for Health (ASTONISH)

Date du début: 1 juin 2016, Date de fin: 31 mai 2019,

The ageing population and related increase in chronic diseases put considerable pressure on both the healthcare system and the society, resulting in an unsustainable rise of healthcare costs. As a result there is an urgent need to improve efficiency of care and reduce hospitalisation time in order to control cost and increase quality of life. Addressing this need, medical applications need to beco ...
Voir le projet

 25

 TERMINÉ 

Combination therapies for personalized cancer medicine (COMBATCANCER)

Date du début: 1 mai 2013, Date de fin: 30 avr. 2019,

All cancers arise due to alterations in their genomes. Although insight into the genetic lesions in tumours by genome sequencing does already assist in selecting some drug regimens, it rarely results in disease eradication due to the emergence of drug-resistant clones. More sophisticated combination therapies in which several oncogenic pathways are targeted simultaneously or in a particular seque ...
Voir le projet

 2

 TERMINÉ 

Leading Innovative measures to reach gender Balance in Research Activities (LIBRA)

Date du début: 1 oct. 2015, Date de fin: 31 mars 2019,

The main goals of LIBRA are to implement innovative Gender Equality Plans (GEPs) that will empower women researchers to achieve successful careers in science, remove gender barriers and biases at an institutional level, and raise awareness of gender aspects in the experimental design of pre-clinical research projects. To achieve these goals we will: 1) conduct an initial external assessment of eac ...
Voir le projet

 11

 TERMINÉ 

Mechanistic insights into the impact of tumor-associated neutrophils on metastatic breast cancer (InflaMet)

Date du début: 1 mars 2014, Date de fin: 28 févr. 2019,

Metastatic disease is still largely unexplored, poorly understood and incurable. Accumulating evidence indicates that cells and mediators of the immune system can facilitate metastasis. Neutrophil accumulation in cancer patients has been associated with metastasis formation. In mouse tumor models, neutrophils have been reported to be pro- or anti- metastatic, but the underlying mechanisms involved ...
Voir le projet

 1

 TERMINÉ 

Advanced T-cell Engineered for Cancer Therapy (ATECT)

Date du début: 1 déc. 2013, Date de fin: 30 nov. 2018,

"T-cell engineering strategies for Cancer therapy, either Chimeric Antigen Receptors (CARs) or TCR transfer holds promise to revolutionize cancer treatment. There are, however, considerable barriers to be overcome to take this form of therapy to a format that can benefit all EU citizens with a wide range of common cancers. The aim of this consortium is to exploit advances in T-cell engineering to ...
Voir le projet

 6

 TERMINÉ 

World-wide E-infrastructure for structural biology (West-Life)

Date du début: 1 nov. 2015, Date de fin: 31 oct. 2018,

The focus of structural biology is shifting from single macromolecules produced by simpler prokaryotic organisms, to the macromolecular machinery of higher organisms, including systems of central relevance for human health. Structural biologists are expert in one or more techniques. They now often need to use complementary techniques in which they are less expert. Instruct supports them in using m ...
Voir le projet

 10

 TERMINÉ 

Exploring enhancers’ Achilles Heel (enhReg)

Date du début: 1 oct. 2013, Date de fin: 30 sept. 2018,

Enhancers are genomic domains that regulate transcription of distantly located genes and that are characterized by specific chromatin signatures of histone methylation and acetylation patterns. Interestingly, RNA polymerase II (RNAPII) binds to a subset of enhancers and produces transcripts, called enhancer RNAs (eRNAs). These are produced bi-directionally and, in contrast to mRNAs and many other ...
Voir le projet

 1

 TERMINÉ 

APERIM: Advanced bioinformatics platform for PERsonalised cancer IMmunotherapy (APERIM)

Date du début: 1 mai 2015, Date de fin: 30 avr. 2018,

Cancer treatment platforms that involve the use of the adaptive immune system have demonstrated profound tumour regressions including complete cure. Importantly, technological advances in next-generation sequencing (NGS) allow for the first time the development of personalised cancer immunotherapies that target patient specific mutations. However, clinical application is currently hampered by spec ...
Voir le projet

 11

 TERMINÉ 

Identification and functional validation of drugable targets/pathways for triple negative breast cancer (Triple-BC)

Date du début: 1 avr. 2013, Date de fin: 31 mars 2018,

Patients suffering from triple-negative breast cancer (TNBC) have a poor prognosis as these tumors frequently confer resistance against chemotherapeutic agents and lack drug targets such as estrogen receptor, progesterone receptor, and epidermal growth factor receptor 2. Insufficient knowledge on the biology of this specific breast tumor type and its heterogeneity hinder the identification of pot ...
Voir le projet

 3

 TERMINÉ 

European Lead Factory (EUC²LID)

Date du début: 1 janv. 2013, Date de fin: 31 déc. 2017,

The European Lead Factory concept proposed by the EUC2LID Consortium relates to the discovery of novel small molecule candidates to serve as starting points for subsequent optimization to either drug candidates or high-quality pharmacological tools for the experimental validation of targets. The concept intends to bridge academic and applied research interests. The European Lead Factory will provi ...
Voir le projet

 34

 TERMINÉ 

Identification of Host Determinants for Virus Entry using a Haploid Genetic Approach (Viral Host Factors)

Date du début: 1 janv. 2013, Date de fin: 31 déc. 2017,

The most powerful and direct way to get insight into complex biological systems is to remove individual components and observe the consequences. Cultured human cells are widely used to model and study aspects of human disease. Although human cells can be analyzed and manipulated in numerous ways, their genome has remained refractory to efficient mutagenesis-based analysis.We have developed an inse ...
Voir le projet

 1

 TERMINÉ 

Adoptive engineered T cell Trials to Achieve Cancer Killing (ATTACK)

Date du début: 1 déc. 2012, Date de fin: 30 nov. 2017,

The aim of this research is to exploit technology for nucleic acid delivery through the clinical testing of adoptive engineered T cells to treat cancer. Recent innovative developments in cancer gene-immunotherapy have led to very encouraging early clinical results. However, the use of engineered T cells is a challenging and complex field with further development and more proof-of-principle trials ...
Voir le projet

 16

 TERMINÉ 

A treatment for BRAF inhibitor resistant melanoma (2MoveMate4Melanoma)

Date du début: 1 mai 2016, Date de fin: 31 oct. 2017,

Some 50% of human melanoma tumors have activating mutations in the BRAF gene. BRAF inhibitor drugs given either alone or in combination with MEK inhibitors have improved progression-free and overall survival in patients with BRAF mutant metastatic melanoma. However, drug resistance invariably limits the duration of clinical benefit of such treatments and is almost always associated with re-activat ...
Voir le projet

 1

 TERMINÉ 

The European non-coding RNA network (RNATRAIN)

Date du début: 1 oct. 2013, Date de fin: 30 sept. 2017,

"Non-coding RNA (ncRNA) is a new research field in rapid development. It holds the potential to explain many fundamental biological phenomena and there is a vast prospective for the development of ncRNA-derived diagnostic and therapeutic tools. Hence, biotech and pharmaceutical companies are actively looking into this unexplored territory for novel targets. Therefore, there is a substantial and un ...
Voir le projet

 11

 TERMINÉ 

Adaptive and innovative Radiation Treatment FOR improving Cancer patients treatment outcomE (ARTFORCE)

Date du début: 1 avr. 2011, Date de fin: 30 sept. 2017,

Loco-regional treatment is the mainstay of cancer cures in non small lung and head and neck cancer. For advanced stage cancer, dose intense multimodality treatment is required yet affected by substantial side effects. Our aim is to improve treatment outcome in locally advanced head and neck and lung cancer patients by:1. Optimizing local control by introducing novel radiation techniques resulting ...
Voir le projet

 14

 TERMINÉ 

Genome-wide identification of factors controlling the telomere damage response and telomere-driven genomic instability (Telomeres)

Date du début: 1 oct. 2012, Date de fin: 30 sept. 2017,

Telomeres are specialized nucleoprotein complexes that protect chromosome ends against recognition as DNA breaks. In somatic cells telomeres shorten every cell division, eventually compromising telomere function. This leads to activation of a DNA damage response that induces irreversible growth arrest or cell death and serves to suppress tumorigenesis by preventing outgrowth of incipient cancer ce ...
Voir le projet

 1

 TERMINÉ 

The impact of chromosomal instability on health: Molecular causes and consequences of aneuploidy (PLOIDYNET)

Date du début: 1 oct. 2013, Date de fin: 30 sept. 2017,

Aneuploidy, an abnormal number of chromosomes, is a hallmark of cancer cells, affecting the majority of all human tumours. Aneuploidy arises when errors occur during mitosis, as the duplicated chromosomes are distributed between the two new daughter cells. Paradoxically, aneuploidy appears to have detrimental consequences for the physiology of untransformed cells in vitro, inhibiting rather than s ...
Voir le projet

 14

 TERMINÉ 

Breaking down arenavirus cell entry (BRACE)

Date du début: 1 oct. 2015, Date de fin: 30 sept. 2017,

Hemorrhagic fever viruses are serious human threats for which we don’t have adequate treatments available, which is painfully highlighted by the current Ebola virus outbreak in Western Africa. These viruses are obligatory intracellular parasites that make use of the host machinery at every phase of their infection cycle. Virus attachment and entry are the initial steps, which requires engagement o ...
Voir le projet

 1

 TERMINÉ 

Quantitative T cell Immunology (QuanTI)

Date du début: 1 mai 2013, Date de fin: 30 avr. 2017,

The primary objective of this ITN is to train a new generation of European quantitative immunologists, who will be able to address challenges arising in Systems Immunology. This will be achieved with the proposed Network, Quantitative T cell Immunology (QuanTI), that will train 11 ESRs and 4 ERs, bringing together renowned experimental and theoretical scientists from private and academic instituti ...
Voir le projet

 12

 TERMINÉ 

Rational molecular Assessments and Innovative Drug Selection (RAIDS)

Date du début: 1 oct. 2012, Date de fin: 31 mars 2017,

Cervical cancer (CC) is the second most common cause of cancer deaths in women worldwide. The main objective of the RAIDs project is to use this model system which is accessible to repeat biopsies to learn how to stratify patients into targeted therapies. The patients’ tumors will be classified into molecular subtypes based on their molecular profile by use of high-throughput technologies (sequen ...
Voir le projet

 19

 TERMINÉ 

Principles of Chromatin Organization (CHROMATINPRINCIPLES)

Date du début: 1 mars 2012, Date de fin: 28 févr. 2017,

"Chromatin is the ensemble of genomic DNA and hundreds of structural and regulatory proteins. Together these proteins govern the gene expression program of a cell. While biochemical and genetic approaches have tought us much about interactions between individual chromatin proteins, we still lack a “big picture” of chromatin: how is the entire interaction network of chromatin proteins organized?My ...
Voir le projet

 1

 TERMINÉ 

Mapping the life histories of T cells (Life-his-T)

Date du début: 1 mai 2011, Date de fin: 31 janv. 2017,

T cells display many different phenotypes and functions, depending on the nature of previously encountered signals. If we want to understand how these different T cell subsets arise, we need to be able to follow individual T cells and their progeny through time. With the aim to map the life histories of individual T cells we have developed unique technologies that allow us to determine whether dif ...
Voir le projet

 1

 TERMINÉ 

Epidemiological study to quantify risks for paediatric computerized tomography and to optimise doses (EPI-CT)

Date du début: 1 févr. 2011, Date de fin: 31 janv. 2017,

Diagnostic radiation represents an indispensable, sometimes life-saving, tool in modern medicine. However, the growing use of computerized tomography (CT) is a topic of concern in radiological protection, especially for children and adolescents. Children are generally more sensitive to the carcinogenic effects of ionizing radiation than adults. In addition, they have a longer life-span to express ...
Voir le projet

 22

 TERMINÉ 

A European Platform for Translational Cancer Research (EUROCANPLATFORM)

Date du début: 1 janv. 2011, Date de fin: 31 déc. 2016,

Europe has a number of advantages as regards developing translational cancer research, yet there is no clear European strategy to meet the increasing burden posed by cancer. The FP6 Eurocan+Plus project analysed the barriers underlying the increasing fragmentation of cancer research and stressed the need to improve collaboration between basic/preclinical and comprehensive cancer centres (CCCs), in ...
Voir le projet

 29

 TERMINÉ 

Rational Therapy for Breast Cancer: Individualized Treatment for Difficult-to-Treat Breast Cancer Subtypes (RATHER)

Date du début: 1 janv. 2011, Date de fin: 31 déc. 2016,

"Cancer genotyping has identified a number of correlations between mutations in specific genes and responses to targeted anti-cancer drugs, with many mutations occurring in kinases or downstream signaling components. While there are several ongoing large-scale genome re-sequencing studies for the major cancer types, there is no systematic effort to investigate kinase mutations in distinct biologic ...
Voir le projet

 8

 TERMINÉ 

Development of mouse mutant resources for functional analyses of human diseases - Enhancing the translation of research into innovation (INFRAFRONTIER-I3)

Date du début: 1 janv. 2013, Date de fin: 31 déc. 2016,

The mouse shows great similarities in development, physiology and biochemistry to humans, which makes it a key model for research into human disease. The major challenges for mouse functional genomics in the 21st century are to:• Develop a series of mutant alleles for every gene in the mouse genome• Determine the phenotypic consequences of each mutation• Identify mouse models for the complete dise ...
Voir le projet

 24

 TERMINÉ 

Towards clinical translation of new gene targeting technologies for correcting inherited mutations and empowering adoptive immunotherapy of cancer (SUPERSIST)

Date du début: 1 mai 2013, Date de fin: 31 oct. 2016,

Substantial evidence supports the therapeutic potential of ex vivo gene therapy based on Hematopoietic Stem Cell (HSC) or T lymphocytes to treat inherited diseases or cancer. Yet, the intrinsic limitations of current gene replacement approaches based on semi-randomly integrating vectors, and the occurrence in some clinical trials of severe adverse events related to gene transfer, prevent safe depl ...
Voir le projet

 5

 TERMINÉ 

Tumor Infiltrating Myeloid Cell Compartment (TIMCC)

Date du début: 1 nov. 2012, Date de fin: 31 oct. 2016,

"The ITN TIMCC brings together eight expert teams from different disciplines within Immunology, Genetics and Oncology, to provide substantive and methodological training in the analysis of the role of the Tumor Infiltrating Myeloid Cell Compartment (TIMCC) of the innate immune system. Leukocytes recruited to (pre)malignant tissues are mainly myeloid cells. They can either prevent or functionally c ...
Voir le projet

 8